Morgan Stanley lowered the firm’s price target on Vir Biotechnology (VIR) to $23 from $24 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Analyst Maintains Buy Rating and $20 Price Target on Vir, Citing Strengthened Oncology Franchise and Favorable Hepatitis Delta Outlook
- Vir Biotechnology Signals Momentum in Latest Earnings Call
- Vir Biotechnology Earns Buy Rating on Advancing Oncology and Hepatitis Delta Pipelines and Strong Cash Runway Into 2028
- Vir Biotechnology reports Q1 EPS (85c) vs. (88c) last year
- Analyst Reiterates Buy on Vir Biotechnology, Citing Best-in-Class HDV Profile and Maintaining $18 Price Target